- Previous Close
0.00 - Open
20.49 - Bid 15.10 x 40000
- Ask 20.70 x 40000
- Day's Range
20.49 - 20.49 - 52 Week Range
18.30 - 21.54 - Volume
18,824 - Avg. Volume
0 - Market Cap (intraday)
4.54B - Beta (5Y Monthly) -0.35
- PE Ratio (TTM)
23.36 - EPS (TTM)
0.86 - Earnings Date May 13, 2025
- Forward Dividend & Yield 0.26 (1.28%)
- Ex-Dividend Date Mar 28, 2025
- 1y Target Est
--
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin, lip balms, sunscreens, functional cosmetics, etc.; medicine for internal use, such as digestive and herbal medicines; regenerative medicines; OTC pharmaceutical products, including ophthalmic, dermatological, gastrointestinal, and diagnostic drugs, as well as Chinese herbal medicines, and supplements. In addition, the company operates beauty counters that provide beauty and health services; and manufactures and sells diagnostic reagents, as well as provides investment management services; and contract development and manufacturing services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.
www.rohto.co.jp7,259
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: RPHCF
View MorePerformance Overview: RPHCF
Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPHCF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPHCF
View MoreValuation Measures
Market Cap
3.66B
Enterprise Value
3.50B
Trailing P/E
23.38
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.34
Price/Book (mrq)
2.67
Enterprise Value/Revenue
1.66
Enterprise Value/EBITDA
12.18
Financial Highlights
Profitability and Income Statement
Profit Margin
10.01%
Return on Assets (ttm)
6.17%
Return on Equity (ttm)
11.49%
Revenue (ttm)
295.57B
Net Income Avi to Common (ttm)
29.59B
Diluted EPS (ttm)
0.86
Balance Sheet and Cash Flow
Total Cash (mrq)
61.71B
Total Debt/Equity (mrq)
14.52%
Levered Free Cash Flow (ttm)
--